Not yet recruitingPhase 2

A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes

A Phase 2, Parallel-Group, Double-Blind Study to Investigate Weight Management With LY4086940 Compared With Placebo in Adult Participants With Obesity or Overweight and Without Type 2 Diabetes

Lead sponsor

Eli Lilly and Company

Asset

LY4086940

Oral · GLP-1 / GIP / glucagon triple

Listed sites

Recruiting sites

Estimated enrollment

460

Study population

Obesity / overweight

Eligibility highlights

Primary endpoint

•Body Weight

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07890376

Org study ID27946

Secondary IDW8M-MC-OG01Eli Lilly and Company

Timeline

Milestones

Study first posted2026-10-22actual

Last update posted2026-11-03actual

Study start2026-11estimated (month precision)

Primary completion2028-01estimated (month precision)

Study completion2028-06estimated (month precision)

Assets

Investigational agents

LY4086940

Who this study enrolls

Obesity / overweight

Who can enroll

Minimum age18 Years

Maximum age75 Years

SexAll

Healthy volunteersNot accepted

Inclusion criteria

•Meet inclusion criteria under Master Protocol CWMM (NCT06143956)

Exclusion criteria

In addition to exclusion criteria under Master Protocol CWMM (NCT06143956)

•Have any prior diagnosis of type 2 diabetes, type 1 diabetes, or rare forms of diabetes mellitus, except gestational diabetes

•Have a laboratory value suggestive of diabetes

•Have any of the following cardiovascular conditions within 6 months prior to screening:

-acute myocardial infarction

-cerebrovascular accident (stroke)

-unstable angina, or

-hospitalization due to congestive heart failure

•Have a known personal or family history (first-degree relative) of multiple endocrine neoplasia type 2A or 2B, thyroid C-cell hyperplasia, or medullary thyroid carcinoma.

•Within 6 months prior to screening, have taken medications (prescribed or over the counter) or alternative remedies (including herbal or nutritional supplements) that promote weight loss

Endpoints (5)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Weight & body composition

Safety / tolerability / PK

Weight & body composition

3 endpoints

Primary/protocol endpoint

Percent Change from Baseline in Body Weight

Time frame:Baseline, Week 32

percent change from baseline, improvement

Secondary/protocol endpoint

Percent Change from Baseline in Body Weight

Time frame:Baseline, Week 48

percent change from baseline, improvement

Secondary/protocol endpoint

Change from Baseline Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQOL-Lite-CT)

Time frame:Baseline, Week 32, Week 48

change from baseline, improvement

Safety / tolerability / PK

2 endpoints

Secondary/protocol endpoint

Pharmacokinetics (PK): Area Under the Curve (AUC) of LY4086940 for One Dosing Interval at Steady State

Time frame:Week 48

concentration, descriptive

Secondary/protocol endpoint

PK: Maximum Concentration (Cmax) of LY4086940 at Steady State

Time frame:Week 48

concentration, descriptive

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateNovember 5, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the November 5, 2026 snapshot.